Amylyx Pharmaceuticals Inc(AMLX)
$31.80+0.89 (+2.88%)
AMLX
Amylyx Pharmaceuticals Inc financials statements
$31.80
At close:+0.89 (+2.88%)
Want to see AMLX full AI Analyst Report?
Amylyx Pharmaceuticals Inc (AMLX) Ratios
723 Followers
Amylyx Pharmaceuticals Inc Ratios
AMLX's free cash flow for Q3 2026 was $-33.70M. For the 2026 fiscal year, AMLX's free cash flow was decreased by $-25.00K and operating cash flow was $-33.67M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 14.27 | 6.67 | 5.66 | 8.20 | 6.03 |
| Quick Ratio | 14.27 | 6.67 | 5.20 | 7.99 | 6.03 |
| Cash Ratio | 9.99 | 2.72 | 2.07 | 1.34 | 2.89 |
| Solvency Ratio | -5.27 | -10.42 | 0.60 | -3.89 | -0.34 |
| Operating Cash Flow Ratio | -5.44 | -5.90 | 0.15 | -3.86 | -4.30 |
| Short-Term Operating Cash Flow Coverage | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Current Asset Value | $ 296.29M | $ 160.56M | $ 380.64M | $ 331.29M | $ -151.83M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.02 | 0.01 | 0.01 | 0.02 | 0.00 |
| Debt-to-Equity Ratio | 0.02 | 0.01 | 0.01 | 0.02 | 0.00 |
| Debt-to-Capital Ratio | 0.02 | 0.01 | 0.01 | 0.02 | 0.00 |
| Long-Term Debt-to-Capital Ratio | 0.02 | 0.00 | 0.00 | 0.00 | 0.00 |
| Financial Leverage Ratio | 1.09 | 1.18 | 1.19 | 1.15 | -0.70 |
| Debt Service Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Debt to Market Cap | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.06 | 0.03 | 0.06 | 0.09 | 0.00 |
| Net Debt to EBITDA | 1.53 | 0.26 | -4.16 | 0.28 | 0.61 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 51.75% | 93.32% | 86.54% | 0.00% |
| EBIT Margin | 0.00% | -334.07% | 10.19% | -905.72% | 0.00% |
| EBITDA Margin | 0.00% | -333.03% | 10.48% | -903.53% | 0.00% |
| Operating Profit Margin | 0.00% | -360.22% | 10.19% | -905.72% | 0.00% |
| Pretax Profit Margin | 0.00% | -345.81% | 14.26% | -888.89% | 0.00% |
| Net Profit Margin | 0.00% | -345.36% | 12.94% | -892.38% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | -345.36% | 12.94% | -892.38% | 0.00% |
| Net Income Per EBT | 100.03% | 99.87% | 90.74% | 100.39% | 100.00% |
| EBT Per EBIT | 94.39% | 96.00% | 139.93% | 98.14% | 106.34% |
| Return on Assets (ROA) | -43.51% | -155.83% | 9.52% | -50.68% | -83.26% |
| Return on Equity (ROE) | -47.41% | -183.14% | 11.37% | -58.24% | 58.17% |
| Return on Capital Employed (ROCE) | -49.46% | -190.48% | 8.91% | -58.39% | -93.73% |
| Return on Invested Capital (ROIC) | -49.26% | -188.50% | 8.04% | -58.04% | -93.73% |
| Return on Tangible Assets | -43.51% | -155.83% | 9.52% | -50.68% | -83.26% |
| Earnings Yield | -12.67% | -117.15% | 4.98% | -8.07% | -8.41% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 195.46 | 9.51 | 1.45 | 0.00 |
| Payables Turnover | 0.15 | 14.34 | 1.15 | 0.48 | 0.00 |
| Inventory Turnover | 0.00 | 0.00 | 0.66 | 0.31 | 0.00 |
| Fixed Asset Turnover | 0.00 | 31.98 | 59.40 | 2.73 | 0.00 |
| Asset Turnover | 0.00 | 0.45 | 0.74 | 0.06 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.32 | 1.06 | 0.11 | 0.00 |
| Cash Conversion Cycle | -2446.54 | -23.58 | 271.70 | 679.61 | 0.00 |
| Days of Sales Outstanding | 0.00 | 1.87 | 38.39 | 251.31 | 0.00 |
| Days of Inventory Outstanding | 0.00 | 0.00 | 549.82 | 1191.34 | 0.00 |
| Days of Payables Outstanding | 2446.54 | 25.45 | 316.51 | 763.05 | 0.00 |
| Operating Cycle | 0.00 | 1.87 | 588.21 | 1442.65 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -1.30 | -2.46 | 0.18 | -2.70 | -1.29 |
| Free Cash Flow Per Share | -1.31 | -2.46 | 0.16 | -2.74 | -1.30 |
| Dividend Paid and CapEx Coverage Ratio | -893.79 | -1067.82 | 9.60 | -71.21 | -211.90 |
| Capital Expenditure Coverage Ratio | -893.79 | -1067.82 | 9.60 | -71.21 | -211.90 |
| Operating Cash Flow Coverage Ratio | -20.71 | -84.63 | 2.81 | -28.66 | 0.00 |
| Operating Cash Flow to Sales Ratio | 0.00 | -1.92 | 0.03 | -8.09 | 0.00 |
| Free Cash Flow Yield | -10.81% | -65.15% | 1.08% | -7.42% | -7.19% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -7.90 | -0.85 | 20.09 | -12.39 | -11.89 |
| Price-to-Sales (P/S) Ratio | 0.00 | 2.95 | 2.60 | 110.55 | 0.00 |
| Price-to-Book (P/B) Ratio | 3.74 | 1.56 | 2.28 | 7.22 | -6.92 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -9.25 | -1.53 | 92.69 | -13.47 | -13.91 |
| Price-to-Operating Cash Flow Ratio | -9.26 | -1.54 | 83.03 | -13.66 | -13.98 |
| Price-to-Earnings Growth (PEG) Ratio | 0.12 | 0.00 | -0.16 | -0.13 | -0.13 |
| Enterprise Value Multiple | -6.39 | -0.63 | 20.65 | -11.96 | -12.05 |
| Enterprise Value | 921.66M | 182.17M | 823.73M | 2.40B | 995.41M |
| EV to EBITDA | -6.39 | -0.63 | 20.65 | -11.96 | -12.05 |
| EV to Sales | 0.00 | 2.08 | 2.16 | 108.02 | 0.00 |
| EV to Free Cash Flow | -7.46 | -1.09 | 77.14 | -13.17 | -13.25 |
| EV to Operating Cash Flow | -7.47 | -1.09 | 69.11 | -13.35 | -13.31 |
| Tangible Book Value Per Share | 3.23 | 2.42 | 6.45 | 5.12 | -2.61 |
| Shareholders’ Equity Per Share | 3.23 | 2.42 | 6.45 | 5.12 | -2.61 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | -0.00 | 0.00 | 0.09 | -0.00 | 0.00 |
| Revenue Per Share | 0.00 | 1.28 | 5.66 | 0.33 | 0.00 |
| Net Income Per Share | -1.53 | -4.43 | 0.73 | -2.98 | -1.52 |
| Tax Burden | 1.00 | 1.00 | 0.91 | 1.00 | 1.00 |
| Interest Burden | 1.00 | 1.04 | 1.40 | 0.98 | 1.06 |
| Research & Development to Revenue | 0.00 | 1.19 | 0.34 | 4.20 | 0.00 |
| SG&A to Revenue | 0.00 | 1.31 | 0.47 | 5.52 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.38 | 0.10 | 0.98 | 0.00 |
| Income Quality | 0.85 | 0.56 | 0.24 | 0.91 | 0.85 |
Currency in USD
